Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats

Respirology

Volumn 14, Issue 7, 2009, Pages 975-982

  Pan, Jin Bing ^a,b   Hou, Yu Hong ^a   Zhang, Guo Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Bleomycin; Inflammation; Phosphodiesterase 4; Phosphodiesterase 4 inhibitor; Pulmonary fibrosis; Rolipram

Indexed keywords

BLEOMYCIN A5; COLLAGEN; CYCLIC AMP; MALONALDEHYDE; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; LUNG FIBROSIS; LUNG HOMOGENATE; LUNG INJURY; LUNG LAVAGE; MALE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RAT;

ANIMALS; BLEOMYCIN; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; HYDROXYPROLINE; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MALONDIALDEHYDE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; ROLIPRAM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70049085116     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01606.x     Document Type: Article

References (42)

1. Lagente V, Manoury B, Nénan S, Le Quément C, Martin-Chouly C et al. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz. J. Med. Biol. Res. 2005 38 : 1521 1530.
2. Smith RE, Strieter RM, Phan SH, Lukacs N, Kunkel SL. TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. J. Leukoc. Biol. 1998 64 : 528 536.
3. Kroegel C, Mock B, Hengst U, Reissig A. Interferon-gamma-1b: therapeutic option in advanced idiopathic pulmonary fibrosis? Respiration 2004 71 : 656 657.
4. Giri SN. Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century. Annu. Rev. Pharmacol. Toxicol. 2003 43 : 73 95.
5. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 2001 134 : 136 151.
6. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J. Rare Dis. 2008 3 : 8.
7. Lagente V, Moodley I, Perrin S, Mottin G, Junien JL. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. Eur. J. Pharmacol. 1994 255 : 253 256.
8. Lagente V, Pruniaux MP, Junien JL, Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am. J. Respir. Crit. Care Med. 1995 151 : 1720 1724.
9. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci. 1997 18 : 164 171.
10. Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am. J. Respir. Cell Mol. Biol. 2002 26 : 694 701.
11. Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C et al. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci. 2004 75 : 823 840.
12. Katzenstein A-L, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 1998 157 : 1301 1315.
13. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am. J. Respir. Cell Mol. Biol. 2005 33 : 9 13.
14. Snider GL, Celli BR, Goldstein RH, O'Brien JJ, Lucey EC. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Am. Rev. Respir. Dis. 1978 117 : 289 297.
15. Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004 59 : 31 8.
16. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, Crystal RG. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am. Rev. Respir. Dis. 1979 120 : 893 899.
17. Piguet PF. Cytokines involved in pulmonary fibrosis. Int. Rev. Exp. Pathol. 1993 34 : 173 181.
18. Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis. Crit. Rev. Immunol. 2005 25 : 429 463.
19. Noble PW, Jiang D. Matrix regulation of lung injury, inflammation, and repair: the role of innate immunity. Proc. Am. Thorac. Soc. 2006 3 : 401 404.
20. Schudt C, Tenor H, Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J. 1995 8 : 1179 1183.
21. Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid. Redox Signal. 2008 10 : 287 301.
22. Armstrong RA. Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br. J. Pharmacol. 1995 116 : 2903 2908.
23. Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br. J. Pharmacol. 2006 147 : S252 7.
24. Barnette MS. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog. Drug Res. 1999 53 : 193 229.
25. Spina D. The potential of PDE4 inhibitors in asthma or COPD. Curr. Opin. Investig. Drugs 2000 1 : 204 213.
26. Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. J. Pharm. Pharmacol. 1996 48 : 46 52.
27. Nash JR, McLaughlin PJ, Butcher D, Corrin B. Expression of tumor necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology 1993 22 : 343 347. (Pubitemid 23159794)
28. Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J. Clin. Invest. 1995 96 : 250 259.
29. Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am. J. Respir. Cell Mol. Biol. 2005 32 : 342 349.
30. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. 1989 170 : 655 663.
31. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J. Pharmacol. Exp. Ther. 1998 287 : 705 711.
32. Corbel M, Belleguic C, Boichot E, Lagente V. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol. Toxicol. 2002 18 : 51 61.
33. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol. 1996 118 : 649 658.
34. Gonçalves de Moraes VL, Singer M, Vargaftig BB, Chignard M. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br. J. Pharmacol. 1998 123 : 631 636.
35. Ouaged M, Martin-Chouly CAE, Leportier C, Belleguic C, Delaval P et al. The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNF-alpha production in whole blood of COPD patients. Fund. Clin. Pharmacol. 2002 16 : 369.
36. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am. J. Pathol. 1991 138 : 1257 1265.
37. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002 122 : S286 9.
38. Houslay MD, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem. Sci. 1997 22 : 217 224.
39. Kohyama T, Ertl RF, Valenti V, Spurzem J, Kawamoto M et al. Prostaglandin E2 inhibits fibroblast chemotaxis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001 281 : L1257 63.
40. Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur. J. Pharmacol. 2007 572 : 12 22.
41. Lindenschmidt RC, Witschi H. Attenuation of pulmonary fibrosis in mice by aminophylline. Biochem. Pharmacol. 1985 34 : 4269 4273.
42. Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008 294 : L24 33.